Roche Diagnostics Operations, Inc.

Universiteit Maastricht

Academisch Ziekenhuis Maastricht

Vinzent Rolny

Johann Karl

Ursula-Henrike Wienhues-Thelen

Andre Ziegler

Roberto Latini

Serge Masson

Dirk Block

Christian Zaugg

Thomas Dieterle

Julia Riedlinger

Edelgard Anna Kaiser

Friedemann Krause

Peter Kastner

Ulrich Schotten

Birgit Wehnl

Thomas Muley

David Conen

Manuel Dietrich

Farshid Dayyani

Ying He

Achim Escherich

Felix Herth

Disclosed is a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure is disclosed.

Circulating ESM-1 (endocan) in the assessment of atrial fibrillation and/or stroke

The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

Circulating Angiopoietin-2 (Ang-2) and insulin-like growth factor-binding protein 7 (IGFBP7) for the prediction of stroke

The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.

Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses

Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.

Biomarkers for risk prediction of mortality

Growing community of inventors

Munich, Germany

Vinzent Rolny